دورية أكاديمية
Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda.
| العنوان: | Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda. |
|---|---|
| المؤلفون: | Zakumumpa H; School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda. zakumumpa.henry09@gmail.com., Alinaitwe A; Joint Clinical Research Centre, Fort Portal Regional Centre of Excellence, Fort Portal, Uganda.; ART Clinic, Fort Portal Regional Referral Hospital, Fort Portal, Uganda., Kyomuhendo M; College of Humanities and Social Sciences, Makerere University, Kampala, Uganda., Nakazibwe B; School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.; Uganda Ministry of Science, Technology and Innovation, Republic of Uganda, Kampala, Uganda. |
| المصدر: | BMC infectious diseases [BMC Infect Dis] 2024 Aug 28; Vol. 24 (1), pp. 876. Date of Electronic Publication: 2024 Aug 28. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BioMed Central, [2001- |
| مواضيع طبية MeSH: | HIV Infections*/drug therapy , Rilpivirine*/therapeutic use , Rilpivirine*/administration & dosage , Health Personnel*/psychology , Anti-HIV Agents*/therapeutic use , Anti-HIV Agents*/administration & dosage, Humans ; Uganda ; Male ; Female ; Adult ; Middle Aged ; Injections, Intramuscular ; Medication Adherence ; Qualitative Research ; Pyridones/administration & dosage ; Pyridones/therapeutic use ; Focus Groups ; Young Adult ; Diketopiperazines |
| مستخلص: | Introduction: Long-acting injectable antiretroviral treatment (LAI-ART) has emerged as a novel alternative to the burden of daily oral pills. The bi-monthly intramuscular injectable containing cabotegravir and rilpivirine holds the promise of improving adherence to ART. The perspectives of potential users of LAI-ART, the majority of whom reside in Eastern and Southern Africa, are still largely unexplored. We set out to understand the experiences of people with HIV (PWH) who received LAI-ART at Fort Portal Regional Referral Hospital in mid-Western Uganda for at least 12 months. Methods: This qualitative study, conducted between July and August 2023, was nested within a larger study. We conducted four focus groups with 32 (out of 69) PWH who received intramuscular injections of cabotegravir and rilpivirine. In-depth interviews were held with six health workers who delivered LAI-ART to PWH. Data were analyzed by thematic approach broadly modeled on the five domains of the Consolidated Framework for Implementation Research (CFIR). Results: There was high acceptability of LAI-ART (30 /32 or 94%) participants requested to remain on LAI-ART even after the end of the 12-month trial. Adherence to ART was reportedly improved when compared to daily oral treatment. Participants credited LAI-ART with; superior viral load suppression, redemption from the daily psychological reminder of living with HIV, enhanced privacy in HIV care and treatment, reduced HIV-related stigma associated with taking oral pills and that it absolved them from carrying bulky medication packages. Conversely, nine participants reported pain around the injection site and a transient fever soon after administering the injection as side effects of LAI-ART. Missed appointments for receiving the bi-monthly injection were common. Providers identified health system barriers to the prospective scale-up of LAI-ART which include the perceived high cost of LAI-ART, stringent cold chain requirements, physical space limitations, and workforce skills gaps in LAI-ART delivery as potential drawbacks. Conclusion: Overall, PWH strongly preferred LAI-ART and expressed a comparatively higher satisfaction with this treatment alternative. Health system barriers to potential scale-up are essential to consider if a broader population of PWH will benefit from this novel HIV treatment option in Uganda and other resource-limited settings. Trial Registration: Trial Registry Number PACTR ID PACTR202104874490818 (registered on 16/04/2021). (© 2024. The Author(s).) |
| References: | Clin Infect Dis. 2022 Nov 21;75(Suppl 4):S549-S556. (PMID: 36410377) Eval Program Plann. 2016 Oct;58:98-105. (PMID: 27347640) BMC Med Res Methodol. 2013 Sep 18;13:117. (PMID: 24047204) AIDS Res Hum Retroviruses. 2021 Feb;37(2):75-88. (PMID: 33176429) J Int Assoc Provid AIDS Care. 2021 Jan-Dec;20:23259582211000517. (PMID: 33685272) BMC Health Serv Res. 2018 Sep 5;18(1):690. (PMID: 30185191) Curr Opin HIV AIDS. 2022 May 1;17(3):127-134. (PMID: 35439787) BMC Health Serv Res. 2017 Jan 23;17(1):65. (PMID: 28114932) AIDS Patient Care STDS. 2020 Feb;34(2):59-71. (PMID: 32049555) PLoS One. 2021 Jul 22;16(7):e0254890. (PMID: 34293033) AIDS Patient Care STDS. 2019 Mar;33(3):104-111. (PMID: 30844308) BMC Health Serv Res. 2020 Mar 17;20(1):222. (PMID: 32183796) J Int AIDS Soc. 2023 Jul;26 Suppl 2:e26101. (PMID: 37439082) AIDS Res Ther. 2022 Nov 26;19(1):56. (PMID: 36435793) J Urban Health. 2023 Oct;100(5):1062-1073. (PMID: 37563518) Br J Clin Pharmacol. 2024 Sep;90(9):2079-2091. (PMID: 38923554) AIDS Care. 2024 May;36(5):703-709. (PMID: 37708454) Infect Chemother. 2021 Dec;53(4):686-695. (PMID: 34979604) BMC Health Serv Res. 2021 Jul 13;21(1):692. (PMID: 34256756) BMC Infect Dis. 2021 Dec 7;21(1):1222. (PMID: 34876050) Clin Infect Dis. 2022 Nov 21;75(Suppl 4):S557-S561. (PMID: 36410379) Drugs. 2020 Apr;80(6):535-545. (PMID: 32180205) BMC Infect Dis. 2023 Feb 17;23(1):98. (PMID: 36803606) BMC Infect Dis. 2022 Aug 15;22(1):692. (PMID: 35971109) J Intellect Disabil. 2013 Sep;17(3):182-97. (PMID: 23801355) BMC Public Health. 2020 Mar 23;20(1):379. (PMID: 32293367) Cult Health Sex. 2021 Aug;23(8):1066-1078. (PMID: 32436478) Ann Pharmacother. 2021 Nov;55(11):1397-1409. (PMID: 33593093) Implement Sci. 2022 Oct 29;17(1):75. (PMID: 36309746) PLoS One. 2021 Jul 22;16(7):e0254214. (PMID: 34292984) Harm Reduct J. 2023 Jan 10;20(1):4. (PMID: 36627679) BMC Health Serv Res. 2021 Apr 1;21(1):302. (PMID: 33794880) Lancet. 2006 Aug 5;368(9534):505-10. (PMID: 16890837) Lancet Glob Health. 2021 May;9(5):e620-e627. (PMID: 33770513) Implement Sci Commun. 2023 Oct 19;4(1):128. (PMID: 37858272) Health Policy Plan. 2024 Jan 23;39(Supplement_1):i21-i32. (PMID: 38253438) Lancet HIV. 2023 Jul;10(7):e428-e429. (PMID: 37419566) J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):263-270. (PMID: 32530905) Lancet Glob Health. 2021 May;9(5):e563-e564. (PMID: 33770512) AIDS Behav. 2024 Jul;28(7):2226-2238. (PMID: 38598026) AIDS Patient Care STDS. 2023 Jun;37(6):316-322. (PMID: 37294280) Soc Sci Med. 2024 Feb;343:116595. (PMID: 38242033) |
| معلومات مُعتمدة: | CARTA/2020/354.707A Consortium for Advanced Research Training in Africa; CARTA/2020/354.707A Consortium for Advanced Research Training in Africa; CARTA/2020/354.707A Consortium for Advanced Research Training in Africa |
| فهرسة مساهمة: | Keywords: ART; Antiretroviral therapy; Global health delivery; HIV treatment; PWH; Uganda |
| المشرفين على المادة: | FI96A8X663 (Rilpivirine) 0 (Anti-HIV Agents) HMH0132Z1Q (cabotegravir) 0 (Pyridones) 0 (Diketopiperazines) |
| تواريخ الأحداث: | Date Created: 20240828 Date Completed: 20240829 Latest Revision: 20240902 |
| رمز التحديث: | 20240902 |
| مُعرف محوري في PubMed: | PMC11360315 |
| DOI: | 10.1186/s12879-024-09748-5 |
| PMID: | 39198739 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1471-2334 |
|---|---|
| DOI: | 10.1186/s12879-024-09748-5 |